Assertio Therapeutics Inc (ASRT) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Assertio Therapeutics Inc (ASRT) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($5.71 Million) in capital expenditures ($180.00K). Check ASRT intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$5.71 Million
USD

Capital Expenditures

$180.00K
USD

Data as of

Dec 2023
Most recent filing

Assertio Therapeutics Inc Capital Reinvestment Ratio (2005–2023)

This chart tracks Assertio Therapeutics Inc's Capital Reinvestment Ratio across 14 annual periods. For the full cash flow conversion analysis, see Assertio Therapeutics Inc (ASRT) cash flow conversion.

Annual Capital Reinvestment Ratio for Assertio Therapeutics Inc (2005–2023)

Year-by-year Capital Reinvestment Ratio for Assertio Therapeutics Inc from 2005 to 2023. See ASRT FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.01x $49.60 Million $628.00K ▲ +263.2%
2022 0.00x $78.60 Million $274.00K ▼ -63.7%
2021 0.01x $5.52 Million $53.00K ▼ -41.4%
2019 0.02x $90.47 Million $1.48 Million ▼ -78.5%
2018 0.08x $72.50 Million $5.51 Million ▲ +609.1%
2017 0.01x $62.17 Million $666.00K ▼ -75.5%
2016 0.04x $65.50 Million $2.86 Million ▼ -76.5%
2015 0.19x $143.89 Million $26.71 Million ▼ -7.7%
2013 0.20x $9.75 Million $1.96 Million ▲ +1561.4%
2011 0.01x $57.65 Million $698.00K ▼ -96.5%
2009 0.34x $1.84 Million $629.00K ▲ +346.2%
2008 0.08x $3.35 Million $257.00K ▲ +620.8%
2007 0.01x $14.66 Million $156.00K ▼ -61.2%
2005 0.03x $28.82 Million $791.25K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow